Literature DB >> 2311332

Scintigraphic study of radiolabelled interferon-alpha in osteosarcoma patients.

R A Diez1, B Perdereau, M Peter, T Dorval, R Gongora, E T Falcoff.   

Abstract

Interferon-alpha is currently under evaluation as an antineoplastic agent in several types of tumour. Despite its clear in vitro effects, the effectiveness of interferon in vivo is limited. To assess whether this discrepancy reflects pharmacokinetic limitations, the authors analysed interferon distribution in 2 osteosarcoma patients by scintigraphy using 123I-interferon-alpha-2a. Numerical analysis of the scintigraphic records demonstrated that the main organs of elimination were the kidneys, when the calculation was made on the basis of surface area. On the other hand, the apparent total uptake by liver (whose projection surface--i.e. the area exposed to the lens--is greater) was higher, reaching about 25 to 30% of the injected dose. The projection surface of the tumour was able to take up radiolabelled interferon in both cases, resulting in a 4-fold increase in the external radiation count compared with the equivalent region of the contralateral limb (although it is not possible to determine whether the label is present on the tumour itself or on the surrounding inflammatory cells). Thus, interferon-alpha seems able to reach at least the immediate neighbourhood of osteosarcoma mass.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311332     DOI: 10.2165/00003088-199018010-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  13 in total

1.  Continuous intravenous infusion pharmacokinetics of interferon to patients with leukemia.

Authors:  R J Wills; H E Spiegel
Journal:  J Clin Pharmacol       Date:  1985 Nov-Dec       Impact factor: 3.126

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  123I radiolabeling of monoclonal antibodies for in vivo procedures.

Authors:  S L Mills; S J Denardo; G L Denardo; A L Epstein; J S Peng; D Colcher
Journal:  Hybridoma       Date:  1986

4.  Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy.

Authors:  H Heremans; A Billiau; P De Somer
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

5.  Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection.

Authors:  R J Wills; S Dennis; H E Spiegel; D M Gibson; P I Nadler
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

6.  Alpha interferon for induction of remission in hairy-cell leukemia.

Authors:  J R Quesada; J Reuben; J T Manning; E M Hersh; J U Gutterman
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

7.  Studies on purification of human gamma interferon: chromatographic behavior of accompanying IL2 and B-cell helper activity.

Authors:  J Wietzerbin; J P Kolb; A Senik; L Der Stepani; G Andreu; E Falcoff; R Falcoff
Journal:  J Interferon Res       Date:  1984

8.  The lymphatic route--II. Pharmacokinetics of human recombinant interferon-alpha 2 injected with albumin as a retarder in rabbits.

Authors:  V Bocci; M Muscettola; A Naldini; E Bianchi; G Segre
Journal:  Gen Pharmacol       Date:  1986

9.  Involvement of the kidney in catabolism of human leukocyte interferon.

Authors:  T Bino; H Edery; A Gertler; H Rosenberg
Journal:  J Gen Virol       Date:  1982-03       Impact factor: 3.891

10.  Similar biological effects of different low doses of interferon alpha in cancer patients.

Authors:  C Billard; R A Diez; D Ferbus; N Raynaud; T Dorval; P Pouillart; K Nielsen; E Falcoff
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

View more
  1 in total

Review 1.  A role for gamma scintigraphy in cancer immunology and immunotherapy.

Authors:  A C Perkins; M V Pimm
Journal:  Eur J Nucl Med       Date:  1992
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.